Investor Relations

Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, acquiring, and commercializing innovative products utilizing the FDA's 505(b)(2) regulatory pathway.

Eton has a diversified pipeline of product candidates under development across various liquid dosage forms, including injectables, oral liquids, and ophthalmics.

Volume :

Copyright West LLC. Minimum 15 minutes delayed.

News Releases
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Business Progress
March 25, 2019
NDA filing for ET-202 Accepted for Review and Assigned PDUFA Date of October 21, 2019 DEER PARK, Ill. , March 25, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, reported
Read More
Eton Pharmaceuticals Submits New Drug Application for DS-200
March 14, 2019
FDA Previously Granted DS-200 Fast Track Designation DEER PARK, Ill. , March 14, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), today announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for DS-200 via the
Read More
Eton Pharmaceuticals to Present at the 8th Annual SVB Leerink Healthcare Conference
February 21, 2019
DEER PARK, Ill. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today announced that Sean Brynjelsen , Chief Executive Officer, will participate in a fireside chat
Read More
Email Alerts

Eton
Latest Event

Eton Pharma Reports Positive Top-Line Results from Phase III Trial of EM-100 Ophthalmic Solution
More events are coming soon.